FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?

In a significant development for oncology, the U.S. Food and Drug Administration (FDA) is poised to approve Merck’s combination therapy of Welireg plus Keytruda, or Keytruda Qlex, for the adjuvant treatment of clear cell renal cell carcinoma (ccRCC) in patients following nephrectomy. With the agency’s decision deadline arriving on June 19, 2026, regulatory analysts anticipate a green light for the regimen, potentially establishing a new standard of care for post-surgical kidney cancer patients. The approval would mark a major expansion in the utility of Merck’s flagship immunotherapy assets, addressing a critical need for more effective adjuvant treatments to prevent disease recurrence.

The impending decision follows rigorous evaluation of clinical data demonstrating the efficacy of combining Welireg, a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, with Keytruda, Merck’s anti-PD-1 therapy. Sources close to the review process indicate that the application has met the necessary requirements for both safety and efficacy, supporting either a standard or accelerated approval pathway. Should the FDA issue the approval letter as expected, it will provide physicians with a powerful new tool to improve survival outcomes for patients at high risk of recurrence after kidney surgery.